Research programme: receptor tyrosine protein kinase like orphan receptor inhibitors

Drug Profile

Research programme: receptor tyrosine protein kinase like orphan receptor inhibitors

Alternative Names: ROR1 inhibitors - Oncternal Therapeutics, Inc.

Latest Information Update: 06 Jun 2016

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Oncternal Therapeutics, Inc.; University of California, San Diego
  • Class Antibodies; CAR-T cell therapies; Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Jun 2016 Tokalas, Inc. has merged with Oncternal Therapeutics to form Oncternal Therapeutics, Inc.
  • 12 Apr 2016 University of California, San diego and Oncternal Therapeutics enter into a an exclusive worldwide license to develop and commercialise ROR1 inhibitors for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top